Ibrutinib Yields Response in Patients With Chronic GVHD

Video
Conference|American Society of Hematology Annual Meeting & Exposition (ASH)

This video examines a phase I/II study of ibrutinib in patients with chronic GVHD who failed corticosteroids.

Chronic graft vs host disease (GVHD) is a serious complication of allogeneic stem cell transplantation, and among patients who fail corticosteroids there remains an unmet need for an effective therapy.

In this video, Lori Styles, MD, medical director of Pharmacyclics in Sunnyvale, California, discusses a phase I/II study of ibrutinib in patients with chronic GVHD who failed corticosteroids.

Results of the trial (abstract LBA-3) were presented at the 58th Annual Meeting of the American Society of Hematology, held December 3–6 in San Diego, California.

Recent Videos
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Related Content
Many patients reported social/financial vulnerabilities that possibly precluded them from transplant access outside of the phase 2 clinical trial.

Cyclophosphamide-Based GVHD Prophylaxis May Improve Survival in HSCT

Roman Fabbricatore
July 21st 2025
Article

Many patients reported social/financial vulnerabilities that possibly precluded them from transplant access outside of the phase 2 clinical trial.

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

The FDA lifted a clinical hold on a new drug application for tabelecleucel as a treatment for EBV-positive lymphoproliferative disease in May 2025.

Developers Resubmit BLA for Tab-Cel in EBV+ Lymphoproliferative Disease

Roman Fabbricatore
July 15th 2025
Article

The FDA lifted a clinical hold on a new drug application for tabelecleucel as a treatment for EBV-positive lymphoproliferative disease in May 2025.

Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
May 5th 2025
Podcast

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease

Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease

American Society for Transplantation and Cellular Therapy
June 25th 2025
Article

Administering precision-selected donor regulatory T-cell therapy significantly improves GVHD-free, relapse-free survival in patients undergoing allogeneic HCT.

Post-transplant Cyclophosphamide as GVHD Prophylaxis in Patients Receiving Mismatched Unrelated HCT: The PHYLOS Trial

Post-transplant Cyclophosphamide as GVHD Prophylaxis in Patients Receiving Mismatched Unrelated HCT: The PHYLOS Trial

American Society for Transplantation and Cellular Therapy
June 25th 2025
Article

Among 77 enrolled patients, the cumulative incidence of grades 2 to 4 aGVHD at day 100 post-transplantation was 18.2% (95% CI, 10.6–27.6%).